Invention Grant
- Patent Title: Anti-alpha-synuclein antibodies
-
Application No.: US16771993Application Date: 2018-12-13
-
Publication No.: US11261242B2Publication Date: 2022-03-01
- Inventor: Ralph Adams , Patrick Downey , Terence Seward Baker , Kerry Louise Tyson , Lorenzo De Lichtervelde , Daniel John Lightwood , David James McMillan
- Applicant: UCB Biopharma SRL
- Applicant Address: BE Brussels
- Assignee: UCB Biopharma SRL
- Current Assignee: UCB Biopharma SRL
- Current Assignee Address: BE Brussels
- Agency: Medler Ferro Woodhouse & Mills PLLC
- Priority: GB1720975 20171215
- International Application: PCT/EP2018/084697 WO 20181213
- International Announcement: WO2019/115674 WO 20190620
- Main IPC: C07K16/18
- IPC: C07K16/18 ; A61K39/00
Abstract:
The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
Public/Granted literature
- US20210107971A1 ANTI-ALPHA-SYNUCLEIN ANTIBODIES Public/Granted day:2021-04-15
Information query
